Background/Aims: Parathyroid hormone-related peptide (PTHrP) was discovered in 1987 as the tumour product responsible for humoral hypercalcaemia of malignancy (HHM). Pancreatic neuroendocrine tumours (NETs) are uncommon malignancies with an incidence of 1:100,000 population. PTHrP-secreting NETs are rare but are being recognised as a cause of HHM in NETs. We describe the largest series to date and the management of these rare tumours. Methods: One male and 4 female patients were seen in our unit from 1998 to 2006. The average duration of follow-up was 86 months from initial diagnosis. All patients had a histologically confirmed diagnosis of pancreatic NET, all of which were low-grade tumours. PTHrP assay was performed in 4 of 5 cases and was elevated in these patients. Results: Initial management involved surgery in 2 of 5 cases, whilst 2 cases underwent chemotherapy and 1 case was commenced on interferon-α. We discuss the further therapies that all patients underwent and the complexities that arose in managing disease progression as well as resistant hypercalcaemia. Conclusion: PTHrP-secreting tumours should be considered in the differential diagnosis of patients with NETs who present with hypercalcaemia and a disproportionately low PTH. PTHrP tumours may well be underestimated as the assay is difficult to perform and may not be requested. In hypercalcaemic patients the standard management acutely includes intravenous fluids, diuretics and intravenous bisphosphonate. In the further management, somatostatin analogue therapy is the first medical option to consider and we discuss the role of other therapies.

Keywords:
Parathyroid hormone-related peptide, Neuroendocrine tumours, Hypercalcaemia, Liver transplantation, Chemotherapy and somatostatin analogues
1.
Barakat MT, Ashrafian H, Todd JF, Meeran K, Williams GR: Severe hypercalcaemia from secretion of parathyroid hormone-related peptide. Lancet Oncol 2004;5:633–635.
2.
Mannstadt M, Juppner H, Gardella TJ: Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol 1999;277:F665–F675.
3.
Drucker DJ, Asa SL, Henderson J, Goltzman D: The parathyroid hormone-like peptide gene is expressed in the normal and neoplastic human endocrine pancreas. Mol Endocrinol 1989;3:1589–1595.
4.
Asa SL, Henderson J, Goltzman D, Drucker DJ: Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. J Clin Endocrinol Metab 1990;71:1112–1118.
5.
Abraham P, Ralston SH, Hewison M, Fraser WD, Bevan JS: Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure. Postgrad Med J 2002;78:752–753.
6.
Bandyopadhyay P, Baksi S, Bandyopadhyay D, Patel CU: Parathyroid hormone-related protein in pancreatic exocrine cancer associated with hypercalcaemia. Int J Clin Pract 2003;57:140–142.
7.
Burgess JR, Wilkinson S, Lowenthal RM: Parathyroid hormone related protein (PTHrP) mediated hypercalcaemia complicating enteropancreatic malignancy in multiple endocrine neoplasia type 1 (MEN 1). Aust NZ J Med 2000;30:280–281.
8.
Cavestro GM, Mantovani N, Coruzzi P, Nouvenne A, Marcucci F, Franze A, Di MF, Okolicsanyi L: Hypercalcemia due to ectopic secretion of parathyroid related protein from pancreatic carcinoma: a case report. Acta Biomed 2002;73:37–40.
9.
Matsen SL, Yeo CJ, Hruban RH, Choti MA: Hypercalcemia and pancreatic endocrine neoplasia with elevated PTH-rP: report of two new cases and subject review. J Gastrointest Surg 2005;9:270–279.
10.
Mitlak BH, Hutchison JS, Kaufman SD, Nussbaum SR: Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. Horm Metab Res 1991;23:344–346.
11.
Mussig K, Petersenn S, Wehrmann M, Horger M, Vierling P, Haring HU, Gallwitz B: Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia. Eur J Gastroenterol Hepatol 2007;19:719–723.
12.
Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(suppl 4):iv1–iv16.
13.
Solcia E, Kloppel G, Sobin LH, et al: Histological Typing of Endocrine Tumours. WHO International Histological Classification of Tumours. Heidelberg, Springer, 2000.
14.
Gehan EA, Tefft MC: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179–181.
15.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
16.
Miraliakbari BA, Asa SL, Boudreau SF: Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol 1992;23:884–887.
17.
Wu TJ, Lin CL, Taylor RL, Kvols LK, Kao PC: Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 1997;72:1111–1115.
18.
McStay MK, Stubbs M, Savage K, Khan K, Caplin M: Expression of parathyroid hormone-related peptide and its receptor in neuroendocrine tumours (abstract). Endocrine Related Cancer 2003;10:505–506.
19.
Barhoum M, Hutchins L, Fonseca VA: Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Am J Med Sci 1999;318:203–205.
20.
Mantzoros CS, Suva LJ, Moses AC, Spark R: Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour. Clin Endocrinol (Oxf) 1997;46:373–375.
21.
Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041–1044.
22.
Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997;36:607–614.
23.
Wynick D, Ratcliffe WA, Heath DA, Ball S, Barnard M, Bloom SR: Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein. BMJ 1990;300:1314–1315.
24.
van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ: Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006;12:448–456.
25.
Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wangberg B, Ahlman H: Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007;13:327–333.
26.
Tarver DS, Birch SJ: Case report: life-threatening hypercalcaemia secondary to pancreatic tumour secreting parathyroid hormone-related protein – successful control by hepatic arterial embolization. Clin Radiol 1992;46:204–205.
27.
Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO: Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007;18:847–855.
28.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.